ストックスクリーナーアプリを入手
1.99
6.99%
0.13
前日終値:
$1.86
開ける：
$1.87
24時間の取引高:
155.75K
Relative Volume:
0.40
時価総額：
$281.40M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+13.07%
1か月 パフォーマンス:
-34.32%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.75
$2.00
1週間の範囲:
$1.75
$2.00
52週間の値動き範囲:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Compare VRXA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
1.99 | 284.23M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Veraxa Biotech Ag (VRXA) 最新ニュース
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures - Benzinga
Veraxa Biotech AG Ord Shs (VRXA) Institutional Confidence - TradingKey
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
Veraxa Biotech AG Ord Shs (VRXA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire
Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com South Africa
Veraxa Biotech AG Ord Shs (VRXA) Cash Flow - TradingKey
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -
Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Income Statement - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire
Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer, Bolstering Solid Tumor Pipeline - citybuzz -
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn
VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -
Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK
VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer - Quiver Quantitative
VERAXA Taps 20-Year Antibody Expert to Guide New Cancer Treatments - Stock Titan
VERAXA Biotech Receives Positive Regulatory Guidance for BiTAC-TCE Platform from German Authority - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today
symbol__ Stock Quote Price and Forecast - CNN
VERAXA Biotech Receives Regulatory Clarity on BiTAC-TCE Cancer Therapy Platform - citybuzz -
Veraxa Biotech AG Announces Regulatory Progress with Its BiTAC -TCE Development Plan - marketscreener.com
VERAXA Biotech (VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - TradingView
VERAXA Biotech Receives Positive Scientific Advice from Germany's PEI for its BiTAC®-TCE Program - citybiz
Veraxa Biotech receives feedback on BiTAC-TCE program - BioWorld News
VERAXA Biotech AG Receives Scientific Advice from Germany’s PEI on BiTAC-TCE Development Program - Quiver Quantitative
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan - The Manila Times
VERAXA cancer candidate targets two markers while sparing others - Stock Titan
Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan - Bitget
VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention - USA Today
Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D - Yahoo Finance
Veraxa Biotech Ag (VRXA) 財務データ
Veraxa Biotech Ag (VRXA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.84%
0.86%
大文字化:
|
ボリューム (24 時間):